Oral intraepithelial neoplasm (white or red patches of oral cavity) is a precancerous condition of the mouth. People with pre-cancerous mouth growths are at greater risk of developing mouth cancer compared to those who do not have such growths.
The purpose of this study is to see if a drug called sulindac can prevent the development of changes in the mouth that are related to oral pre-cancer growths (oral epithelial dysplasia) or oral cancer. There is no standard medical treatment for this condition.
Sulindac, a capsule that is taken orally, is an anti-inflammatory drug that has already been approved for treating arthritis. It works by inhibiting an enzyme involved in inflammation. Patients in this study will be randomly assigned to receive sulindac or a placebo for six months.